The prognostic and therapeutic values of long noncoding RNA PANDAR in colorectal cancer

Mahdi Rivandi, Alireza Pasdar, Leila Hamzezadeh, Amir Tajbakhsh, Sima Seifi, Mehrdad Moetamani-Ahmadi, Gordon A. Ferns, Amir Avan*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

10 Citations (Scopus)

Abstract

Long noncoding RNAs (lncRNAs) consist of 200 nucleotide sequences that play essential roles in different processes, including cell proliferation, and differentiation. There is evidence showing that the dysregulation of lncRNAs promoter of CDKN1A antisense DNA damage-activated RNA (PANDAR) leads to the development and progression in several cancers including colorectal cancer, via p53-dependent manner. This suggests that these lncRNAs may be of value as prognostic indices and a therapeutic target, as a high expression of lncRNAs PANDAR is associated with poor prognosis. Furthermore, modulating lncRNAs PANDAR has been reported to induce apoptosis and inhibit the tumor growth through modulation of cell cycle and epithelial-mesenchymal transition (EMT) pathway. The aim of the current review was to provide an overview of the prognostic and therapeutic values of lncRNAs PANDAR in colorectal cancer.

Original languageEnglish
Pages (from-to)1230-1236
Number of pages7
JournalJournal of Cellular Physiology
Volume234
Issue number2
Early online date7 Sep 2018
DOIs
Publication statusPublished - 1 Feb 2019

Keywords

  • colorectal cancer
  • lncRNAs promoter of CDKN1A antisense DNA damage-activated RNA (PANDAR)
  • long noncoding RNAs (lncRNAs)
  • prognostic biomarker
  • therapeutic target

Fingerprint

Dive into the research topics of 'The prognostic and therapeutic values of long noncoding RNA PANDAR in colorectal cancer'. Together they form a unique fingerprint.

Cite this